Resultados de la búsqueda 351-360 of 18226 for Ovarian

  1. Oncología (médica) - Ensayos clínicos

    Oncolytic Adenovirus Coding For TNFa And IL2 (TILT-123) With Pembrolizumab Or Pembrolizumab And Pegylated Liposomal Doxorubicin As Treatment For Ovarian Cancer.

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    In this study, we make and test preclinical models of gynecological cancers (ovarian, fallopian tube, peritoneal, uterine, vulvar, cervix, and vaginal) of ...

  3. Síndrome del ovario poliquístico - Mayo Clinic

    Síndrome del ovario poliquístico. Jan. 27, 2023. Original article: https://www.mayoclinic.org/es-es/diseases-conditions/pcos/multimedia/polycystic-ovary- ...

  4. Neurología - Ensayos clínicos - Mayo Clinic

    ... ovarian cancer, (7) advanced, unresectable clear cell kidney cancer, (8) advanced, unresectable bladder cancer, (9) advanced, unresectable lung ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    In this study, we make and test preclinical models of gynecological cancers (ovarian, fallopian tube, peritoneal, uterine, vulvar, cervix, and vaginal) of ...

  6. Cirugía - Ensayos clínicos - Mayo Clinic

    A Safety to Evaluate the Safety and Effectiveness of Pressurized Intraperitoneal Aerosolized Chemotherapy in Ovarian, Uterine, Colorectal, and Gastric Cancer ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to determine the response rate to PLX-038 in patients with metastatic ovarian, primary peritoneal, and fallopian tube cancers ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... ovarian cancer, (7) advanced, unresectable clear cell kidney cancer, (8) advanced, unresectable bladder cancer, (9) advanced, unresectable lung ...

  9. Oncología (médica) - Ensayos clínicos

    Oncolytic Adenovirus Coding For TNFa And IL2 (TILT-123) With Pembrolizumab Or Pembrolizumab And Pegylated Liposomal Doxorubicin As Treatment For Ovarian Cancer.

  10. Oncología (médica) - Ensayos clínicos

    The purpose of this study is to determine the response rate to PLX-038 in patients with metastatic ovarian, primary peritoneal, and fallopian tube cancers ...